These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12163200)

  • 21. The REFLEX study: a missed opportunity?
    Giovannoni G
    Lancet Neurol; 2012 Jan; 11(1):22-4. PubMed ID: 22146410
    [No Abstract]   [Full Text] [Related]  

  • 22. Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis.
    Lana-Peixoto MA; Teixeira AL; Haase VG
    Arq Neuropsiquiatr; 2002 Sep; 60(3-B):721-4. PubMed ID: 12364937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
    Kornhuber ME; Zierz S
    Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
    [No Abstract]   [Full Text] [Related]  

  • 24. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics.
    Rudick RA
    Arch Neurol; 1999 Sep; 56(9):1079-84. PubMed ID: 10488808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis.
    Río J; Porcel J; Téllez N; Sánchez-Betancourt A; Tintoré M; Arévalo MJ; Nos C; Montalban X
    Mult Scler; 2005 Jun; 11(3):306-9. PubMed ID: 15957512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis.
    Turner AP; Williams RM; Sloan AP; Haselkorn JK
    Rehabil Psychol; 2009 Feb; 54(1):116-21. PubMed ID: 19618711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunomodulatory treatment of MS in Slovenia.
    Sega-Jazbec S
    Clin Neurol Neurosurg; 2002 Jul; 104(3):249-50. PubMed ID: 12127663
    [No Abstract]   [Full Text] [Related]  

  • 29. Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate.
    Arbour N; Rastikerdar E; McCrea E; Lapierre Y; Dörr J; Bar-Or A; Antel JP
    Mult Scler; 2005 Dec; 11(6):652-7. PubMed ID: 16320724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacological and clinical profile of IFNbeta-1a (Avonex IM Injection Syringe 30 microg].
    Sumino R
    Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):209-17. PubMed ID: 17379973
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
    Mahurkar S; Suppiah V; O'Doherty C
    Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-term treatment optimization in individuals with multiple sclerosis using disease-modifying therapies: a nursing approach.
    Denis L; Namey M; Costello K; Frenette J; Gagnon N; Harris C; Lowden D; McEwan L; Morrison W; Poirier J
    J Neurosci Nurs; 2004 Feb; 36(1):10-22. PubMed ID: 14998102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a.
    Schott E; Paul F; Wuerfel JT; Zipp F; Rudolph B; Wiedenmann B; Baumgart DC
    World J Gastroenterol; 2007 Jul; 13(26):3638-40. PubMed ID: 17659718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
    Frohman EM; Racke M; van Den Noort S
    Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management.
    Stuart WH
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S19-25. PubMed ID: 15253686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
    Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
    Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction versus escalation therapy.
    Martinelli V; Comi G
    Neurol Sci; 2005 Dec; 26 Suppl 4():S193-9. PubMed ID: 16388357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Local pain during REBIF injection is not due to acidic pH.
    Buttmann M; Goebeler M; Rieckmann P
    J Neurol Neurosurg Psychiatry; 2004 Jul; 75(7):1078. PubMed ID: 15201384
    [No Abstract]   [Full Text] [Related]  

  • 40. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].
    Gusev EI; Boĭko AN; Pozer Ch
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.